Astra’s Experimental Stomach Cancer Drug Doubled Survival Time

AstraZeneca Plc’s experimental stomach cancer drug doubled the time patients survived in a late-stage trial, boosting prospects for a potential new blockbuster.

By Ashleigh Furlong · Bloomberg

AstraZeneca Plc’s experimental stomach cancer drug doubled the time patients survived in a late-stage trial, boosting prospects for a potential new blockbuster.